Drug Trial Radar · NCT00724048
A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
Last checked: Nov 19, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
227
Actual
Start
Oct 24, 2008
Primary completion
Jul 26, 2010
Study completion Jul 26, 2010
Sponsor
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
- Sponsor type
- Industry
- First posted
- Jul 29, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic treatment of Huntington's Disease.
Conditions
- Huntington Disease
Interventions
ACR16Drug
ACR16 will be administered per dose and schedule specified in the arm description.
PlaceboOther
Placebo matching to ACR16 will be administered per schedule specified in the arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the UHDRS Motor Assessments) at Week 12Time frame: Baseline, Week 12
Locations
28 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California
San Diego, California
Colorado Neurological Institute
Littleton, Colorado
University of South Florida
Tampa, Florida
Rush University Medical Center
Chicago, Illinois
Indiana University School of Medicine
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
University of Maryland School of Medicine
Baltimore, Maryland
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Charlestown, Massachusetts
Struthers Parkinson's Center
Saint Louis Park, Minnesota
Washington University School of Medicine
St Louis, Missouri
Albany Medical College
Albany, New York
North Shore-LIJ Health System
Manhasset, New York
University of Rochester
Rochester, New York
University of Cincinnati
Cincinnati, Ohio
Ohio State University Parkinson's Center
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
University of Tennessee Health Science Center
Memphis, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
Baylor College of Medicine
Houston, Texas
Booth Gardner Parkinson's Care Center
Kirkland, Washington
University of Alberta Glenrose Rehab Hospital
Edmonton, Alberta, Canada
University of British Columbia
Vancouver, British Columbia, Canada
London Health Sciences Centre
London, Ontario, Canada
The Centre for Addiction and Mental Health
Markham, Ontario, Canada
Parkinsons and Neurodegenerative Disorders Clinic
Ottawa, Ontario, Canada
Hotel-Dieu Hospital-CHUM
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.